2-羟基-3-(3-羟基苯基)丙酸 | 3247-74-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 2-羟基-3-(3-羟基苯基)丙酸
• 英文名称: α,3-dihydroxy-benzenepropanoic acid
• 英文别名: (+/-)-2-hydroxy-3-(3-hydroxy-phenyl)-propionic acid；(+/-)-2-Hydroxy-3-(3-hydroxy-phenyl)-propionsaeure；3-(3-hydroxyphenyl)-2-hydroxypropionic acid；2-hydroxy-3-(3-hydroxyphenyl)propanoic Acid
• CAS: 3247-74-3
• 化学式: C₉H₁₀O₄
• 分子量: 182.176
• InChiKey: ZVQJWJJKDHMWQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-羟基-3-(3-羟基苯基)丙酸 以43的产率得到(2S)-3-(3-hydroxyphenyl)-2-hydroxypropionic acid (S)-phenylethylamine salt
  参考文献：
  名称：

  Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof

  摘要：

  本发明涉及由式（I）表示的钙双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸酯]，其水合物，该化合物的晶体以及该化合物的水合物的晶体，它们作为药物非常有用，并且涉及其制备方法以及中间体，以及其生产方法。【问题】需要制备纯化的（2S）-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸，以药物物质的形式，以使残留溶剂含量最小化，并具有统一的规格和高度良好的可加工性，以及制备它的方法。【解决方案】晶体钙双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸酯]，即（2S）-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸的钙盐，解决了上述问题。【选定图】无

  公开号：

  US20070117866A1
• 作为产物：
  描述：

  间羟基-2-羰基丙酸 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以99%的产率得到2-羟基-3-(3-羟基苯基)丙酸
  参考文献：
  名称：

  Application of Ruthenium-Induced Macrocyclization for the Construction of Macrocyclic Depsipeptides

  摘要：

  The synthesis of a biaryl ether containing macrocyclic depsipeptide I was achieved in 6% overall yield. The desired macrocycle was constructed by cyclization of a phenol into eta(6)-ruthenium complex. The ruthenium metal was subsequently photolytically deprotected to obtain the macrocycle 1.

  DOI：

  10.1021/jo011106v

文献信息

• A Modified Synthesis of (±)-β-Aryllactic acids
  作者：Henry N. C. Wong、Zun Le Xu、Hson Mou Chang、Chi Ming Lee

  DOI：10.1055/s-1992-26228

  日期：——

  The synthesis of racemic forms of the reportedly active principle of Danshen, namely (±)-ß-(3,4-dihydroxyphenyl)lactic acid [(±)- 3-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid] and its seven racemic derivatives is reported.

  据报道，丹参中活性成分的外消旋形式，即（±）-ß-(3,4-二羟基苯基)乳酸[(±)-3-(3,4-二羟基苯基)-2-羟基丙酸]及其七种外消旋衍生物已成功合成。
• Calcium bis [ (2S) - 3- [3-[ (2S) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
  申请人：Shinoda Masanobu

  公开号：US20070117866A1

  公开（公告）日：2007-05-24

  The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof. [Problem]There is need for (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, in the form of a drug substance, purified so as to minimize a residual solvent content and having a uniformized specification and a highly favorable workability, and a process for producing the same. [Solution]Crystalline calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate], a calcium salt of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, solves the above problem. [Selected Drawing] None

  本发明涉及由化学式（I）表示的双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸钙盐，其水合物，该化合物的晶体，以及该化合物的水合物的晶体，这些都可用作药物，并且涉及生产这些物质的方法，以及其中间体和生产过程。【问题】需要（2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸，以药物物质形式存在，经过纯化以最大程度减少残留溶剂含量，并具有统一的规格和极具可操作性，并提供生产该物质的方法。【解决方案】晶体钙双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸钙盐，是(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸的钙盐，解决了上述问题。【选定图纸】无
• Calcium Bis [ (2S) -3- [3-[ (2S) -3- (4-Chloro-2-Cyanophenoxy) -2- Fluoropropoxy]Phenyl] -2- Isopropoxypropionate] and Intermediate Thereof
  申请人：Shinoda Masanobu

  公开号：US20090069591A1

  公开（公告）日：2009-03-12

  The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof. [Problem] There is need for (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, in the form of a drug substance, purified so as to minimize a residual solvent content and having a uniformized specification and a highly favorable workability, and a process for producing the same. [Solution] Crystalline calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate], a calcium salt of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, solves the above problem. [Selected Drawing] None

  本发明涉及由式（I）表示的双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸钙]，其水合物，该化合物的晶体以及该化合物水合物的晶体，它们作为药物有用，并涉及制备它们的过程以及中间体，以及生产它们的过程。 [问题] 需要制备(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸，以药物物质的形式，经过纯化以最小化残留溶剂含量，并具有统一的规格和高度良好的可操作性，以及制备该物质的过程。 [解决方案] 由式（I）表示的结晶性双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸钙]，即(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸的钙盐，解决了上述问题。 [选定图纸] 无
• Additives enhancing topical actions of therapeutic agents
  申请人：Van Scott, Eugene J., Dr.

  公开号：EP0770399A2

  公开（公告）日：1997-05-02

  Composition and method for enhancing therapeutic effects of topically applied agents are disclosed. The cosmetic or therapeutic composition may include one or more of cosmetic or pharmaceutical agents present in a total amount of from 0.01 to 40 percent and one or more of hydroxycarboxylic acids or related compounds present in a total amount of from 0.01 to 99 percent by weight of the total composition. The cosmetic and pharmaceutical agents may include but not limited to age spots, wrinkles and keratoses removing agents; vitamins; aloes; sun screens; tanning, depigmenting and shampooing agents; antiyeasts; antifungal, antibacterial and antiviral agents; topical bronchial dilators and topical cardiovascular agents; hormonal agents; vasodilators; retinoids and other dermatological agents. The hydroxycarboxylic acids and related compounds include organic alpha and beta hydroxycarboxylic acids, alpha and beta ketocarboxylic acids and salts thereof. Topical application of the cosmetic or therapeutic composition has been found to achieve a substantial increase in cosmetic or therapeutic effect of the active ingredient in humans and domesticated animals.

  本发明公开了增强外用药剂治疗效果的组合物和方法。该化妆品或治疗组合物可包括一种或多种化妆品或药物制剂，其总量为组合物总重量的 0.01% 至 40%，以及一种或多种羟基羧酸或相关化合物，其总量为组合物总重量的 0.01% 至 99%。化妆品和药物制剂可包括但不限于老年斑、皱纹和角化去除剂；维生素；芦荟；防晒霜；美黑、脱色和洗发剂；抗酵母菌；抗真菌、抗细菌和抗病毒剂；局部支气管扩张剂和局部心血管制剂；激素制剂；血管扩张剂；维甲酸和其他皮肤病制剂。羟基羧酸及相关化合物包括有机 alpha 和 beta 羟基羧酸、alpha 和 beta 酮羧酸及其盐类。研究发现，局部使用化妆品或治疗组合物可大大提高活性成分对人类和驯养动物的美容或治疗效果。
• CALCIUM BIS[2S)-3-[3-(2S)-3-(4-CHLORO-2-CYANOPHENOXY)-2- FLUOROPROPOXY¨PHENYL]-2-ISOPROPOXYPROPIONATE] AND INTERMEDIATE THEREOF
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1873141A1

  公开（公告）日：2008-01-02

  The present invention relates to calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are useful as pharmaceuticals, and to processes for producing the same, and intermediates therefore, and processes for production thereof. [Problem] There is need for (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, in the form of a drug substance, purified so as to minimize a residual solvent content and having a uniformized specification and a highly favorable workability, and a process for producing the same. [Solution] Crystalline calcium bis[(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate], a calcium salt of (2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionic acid, solves the above problem.

  本发明涉及由式(I)代表的双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸钙]、其水合物、式(I)化合物的晶体和式(I)化合物的水合物的晶体，它们可用作药物，本发明还涉及生产这些药物的工艺及其中间体和生产工艺。 问题 需要(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸，其形式为药物物质，纯化后可将残留溶剂含量降至最低，并具有均匀的规格和非常有利的加工性，以及生产该物质的工艺。 [解决方案］ 结晶双[(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸]钙盐，即(2S)-3-[3-[(2S)-3-(4-氯-2-氰基苯氧基)-2-氟丙氧基]苯基]-2-异丙氧基丙酸的钙盐，解决了上述问题。